Workflow
Altimmune(ALT)
icon
Search documents
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
Prnewswire· 2025-08-22 14:00
Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for alleged securities fraud and unlawful business practices following disappointing trial results [2][3]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Altimmune and its officers engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Altimmune securities during the Class Period have until October 6, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Trial Results and Market Reaction - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [3]. - The trial results showed a positive trend in fibrosis improvement, but a higher-than-expected placebo response led to the lack of statistical significance [3]. - Following the announcement, Altimmune's stock price fell by $4.10 per share, or 53.2%, closing at $3.61 per share [4].
October 6, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ALT
Prnewswire· 2025-08-22 12:45
Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2]. - The company's stock price experienced a significant decline of 53.2%, dropping from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, following the disappointing trial results [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
GlobeNewswire News Room· 2025-08-21 15:36
Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. regarding allegations of securities fraud and unlawful business practices related to the company's performance and disclosures [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Altimmune and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Altimmune securities during the Class Period have until October 6, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [4]. - The company had previously set inflated expectations for the trial results, but the analysis revealed a higher-than-expected placebo response that contributed to the failure [4]. - Following the announcement of the trial results, Altimmune's stock price fell by $4.10 per share, or 53.2%, closing at $3.61 per share [5].
INVESTOR REMINDER: Berger Montague Notifies Altimmune, Inc. (NASDAQ: ALT) Investors of a Class Action Lawsuit and Deadline
Prnewswire· 2025-08-21 15:06
Core Viewpoint - A class action lawsuit has been filed against Altimmune Inc. by Berger Montague on behalf of investors who acquired the company's securities during the specified class period from August 10, 2023, to June 25, 2025 [1][2]. Company Overview - Altimmune Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focusing on therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) [2]. Legal Action Details - Investors who purchased Altimmune securities during the class period have until October 6, 2025, to seek appointment as lead plaintiff representatives [2]. - The lawsuit follows a press release from Altimmune on June 26, 2025, announcing disappointing results from its IMPACT Phase 2b trial of Pemvidutide for MASH treatment, where the primary endpoint of fibrosis reduction did not achieve statistical significance [3]. Stock Price Impact - Following the announcement of the trial results, Altimmune's stock price plummeted by 53.2% in one day, dropping from a closing price of $7.71 on June 25, 2025, to $3.61 on June 26, 2025 [4].
Contact The Gross Law Firm by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc.(ALT)
Prnewswire· 2025-08-21 12:45
Core Viewpoint - Altimmune, Inc. faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint analysis [1][2]. Group 1: Company Performance - The IMPACT Phase 2b MASH trial results were released on June 26, 2025, revealing that while there was a positive trend in fibrosis improvement, the results did not meet statistical significance due to a higher-than-expected placebo response [1]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [1]. Group 2: Legal Actions - Shareholders who purchased shares of Altimmune during the class period from August 10, 2023, to June 25, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointments in a class action lawsuit [1][2]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is October 6, 2025 [2]. Group 3: Firm's Commitment - The Gross Law Firm is dedicated to protecting the rights of investors affected by deceitful practices and aims to ensure companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that led to artificial inflation of stock prices [3].
ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc.
Prnewswire· 2025-08-20 21:37
Group 1 - A class action has been filed on behalf of investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025 [1] - Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases [1] - The complaint alleges that Altimmune misled investors regarding the viability of its IMPACT Phase 2b MASH trial, which failed to achieve statistical significance due to a higher-than-expected placebo response [2] Group 2 - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price fell from $7.71 to $3.61, a decline of over 53% in one day [2] - Shareholders interested in serving as lead plaintiff must submit their papers by October 6, 2025, and do not need to participate in the case to be eligible for recovery [3] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]
Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights – ALT
GlobeNewswire News Room· 2025-08-19 20:09
Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1] Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2] - The company's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a significant decline of 53.2% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request the Court to appoint them as lead plaintiffs, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
Globenewswire· 2025-08-19 11:30
Core Viewpoint - The FDA has granted Fast Track designation to pemvidutide for the treatment of Alcohol Use Disorder (AUD), highlighting the urgent need for effective treatments in this area [1][3][5] Group 1: Pemvidutide and Clinical Trials - Pemvidutide is currently undergoing a Phase 2 trial named RECLAIM, which is enrolling approximately 100 patients to evaluate its safety and efficacy in treating AUD [2][6] - The trial will randomize participants to receive either 2.4 mg of pemvidutide or a placebo weekly for 24 weeks, with the primary endpoint being the change in the average number of heavy drinking days [2] - Pemvidutide has shown potential in preclinical models to significantly reduce alcohol intake, supporting its use in treating AUD [3][7] Group 2: Market Need and Treatment Gap - An estimated 28 million adults in the U.S. suffer from AUD, yet only 2% are currently treated with medication, indicating a significant treatment gap [3][5] - Existing FDA-approved therapies for AUD have limited efficacy and do not adequately address comorbidities such as hepatic steatosis and hypertension [3][5] - The World Health Organization identifies harmful alcohol consumption as a leading cause of global death and disability, emphasizing the need for effective treatments [4] Group 3: Mechanism and Benefits of Pemvidutide - Pemvidutide acts as a dual receptor agonist for GLP-1 and glucagon, which may help in weight loss and reducing alcohol cravings [6][7] - In previous trials, pemvidutide demonstrated significant improvements in liver fat content, weight loss, and blood pressure, indicating its potential as a comprehensive treatment for AUD and related conditions [7] - The ongoing IMPACT Phase 2b trial is expected to provide further insights into pemvidutide's efficacy in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) and its potential benefits for AUD [7]
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT
Prnewswire· 2025-08-18 12:45
Core Viewpoint - Altimmune, Inc. faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial for Pemvidutide, leading to allegations of inflated expectations by the company [1]. Group 1: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [1]. - The stock price of Altimmune dropped from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [1]. Group 2: Legal Actions - Shareholders who purchased shares of ALT between August 10, 2023, and June 25, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointments in a class action lawsuit [1][2]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is October 6, 2025 [2]. Group 3: Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
GlobeNewswire News Room· 2025-08-16 13:42
Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, of the October 6, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To participate in the class action, investors can submit a form or contact the law firm for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, leading to investor damages when the true results were revealed [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [3]